Rhelion Life Sciences Corp.
RHEL
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.82M | -989.10K | -847.10K | -743.30K | -973.80K |
| Total Depreciation and Amortization | 57.20K | 61.10K | 71.10K | 69.00K | 76.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.16M | 416.70K | 210.50K | 249.30K | 230.40K |
| Change in Net Operating Assets | 265.10K | -63.10K | 16.10K | 133.70K | 284.30K |
| Cash from Operations | -331.50K | -574.50K | -549.40K | -291.30K | -382.50K |
| Capital Expenditure | -1.70K | -2.30K | -1.80K | -95.60K | -27.40K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -71.90K | -224.80K | -336.10K | -151.70K | 0.00 |
| Cash from Investing | -73.60K | -227.10K | -337.80K | -247.30K | -27.40K |
| Total Debt Issued | -176.90K | 176.60K | 0.00 | 4.90K | 22.80K |
| Total Debt Repaid | -25.40K | -25.10K | -33.80K | -686.30K | 50.20K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -145.50K | 108.70K | -24.60K | -492.50K | 50.90K |
| Foreign Exchange rate Adjustments | -500.00 | -16.30K | 20.20K | 30.80K | 43.70K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -551.00K | -709.10K | -891.60K | -1.00M | -315.30K |